Omalizumab in the management of bullous pemphigoid: a six-month retrospective study.

Postepy Dermatol Alergol · 2026 · PMC13178240 · PMID 42148330

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

An increase in the CR rate to 81% was observed when patients received more than 10 doses of omalizumab; nevertheless, the difference did not reach statistical significance [ 15 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.